Literature DB >> 20308121

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.

Chris Deighton1, Kimme Hyrich, Tina Ding, Jo Ledingham, Mark Lunt, Raashid Luqmani, Patrick Kiely, Marwan Bukhari, Rikki Abernethy, Andrew Ostor, Ailsa Bosworth, Kate Gadsby, Frank McKenna, Diana Finney, Josh Dixey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308121     DOI： 10.1093/rheumatology/keq006a

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  14 in total

Review 1.  Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.

Authors:  Poonam Sharma; David G I Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

2.  Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.

Authors:  Ray Fitzpatrick; David Gi Scott; Ian Keary
Journal:  Clin Rheumatol       Date:  2013-07-09       Impact factor: 2.980

3.  High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

Authors:  Florenzo Iannone; Elisa Gremese; Gaia Gallo; Piercarlo Sarzi-Puttini; Costantino Botsios; Francesco Trotta; Stefania Gasperini; Mauro Galeazzi; Silvano Adami; Fabrizio Cantini; Marco Sebastiani; Roberto Gorla; Antonio Marchesoni; Annarita Giardina; Rosario Foti; Angiola Mele; Eleonora Bruschi; Gianluca Bagnato; Gian Luca Erre; Giovanni Lapadula
Journal:  Clin Rheumatol       Date:  2013-08-18       Impact factor: 2.980

4.  Same-day or historical ESR for disease activity score measurement: does it matter?

Authors:  Sven Brode; Muhammad K Nisar; Andrew J K Ostör
Journal:  Clin Rheumatol       Date:  2012-11-24       Impact factor: 2.980

5.  In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register.

Authors:  Suzanne M M Verstappen; Mark Lunt; Diane K Bunn; David G I Scott; Deborah P M Symmons
Journal:  Ann Rheum Dis       Date:  2011-05-08       Impact factor: 19.103

6.  Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study.

Authors:  Sarika Ogale; Elena Hitraya; Henry J Henk
Journal:  BMC Musculoskelet Disord       Date:  2011-09-19       Impact factor: 2.362

Review 7.  Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals.

Authors:  Patrick D W Kiely; Chris Deighton; Josh Dixey; Andrew J K Ostör
Journal:  Rheumatology (Oxford)       Date:  2011-10-27       Impact factor: 7.580

8.  The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice.

Authors:  Tim Blake; Vijay Rao; Tahir Hashmi; Nicola Erb; Sheila Catherine O'Reilly; Shireen Shaffu; Karen Obrenovic; Jon Packham
Journal:  BMC Musculoskelet Disord       Date:  2014-09-02       Impact factor: 2.362

9.  Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs).

Authors:  Niels W Boone; Patty Teeuwisse; Paul-Hugo van der Kuy; Rob Janknegt; Robert B M Landewé
Journal:  Springerplus       Date:  2015-08-28

10.  Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?

Authors:  Aneela N Mian; Fowzia Ibrahim; David L Scott; James Galloway
Journal:  Arthritis Res Ther       Date:  2016-06-16       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.